



## Announcement Summary

---

**Entity name**

STARPHARMA HOLDINGS LIMITED

**Announcement Type**

New announcement

**Date of this announcement**

Monday October 09, 2023

**The +securities to be quoted are:**

☒ +Securities issued under an +employee incentive scheme that are not subject to a restriction on transfer or that are to be quoted notwithstanding there is a restriction on transfer

**Total number of +securities to be quoted**

ASX +security code	Security description	Number of +securities to be quoted	Issue date
SPL	ORDINARY FULLY PAID	121,082	06/10/2023

Refer to next page for full details of the announcement



## Part 1 - Entity and announcement details

---

### 1.1 Name of entity

STARPHARMA HOLDINGS LIMITED

We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.

### 1.2 Registered number type

ABN

### Registration number

20078532180

### 1.3 ASX issuer code

SPL

### 1.4 The announcement is

☒ New announcement

### 1.5 Date of this announcement

9/10/2023



## Part 2 - Type of Issue

---

### **2.1 The +securities to be quoted are:**

☒ +Securities issued under an +employee incentive scheme that are not subject to a restriction on transfer or that are to be quoted notwithstanding there is a restriction on transfer

### **2.2 The +securities to be quoted are:**

☒ Additional +securities in a class that is already quoted on ASX ("existing class")



Part 3B - number and type of +securities to be quoted (existing class) where issue has not previously been notified to ASX in an Appendix 3B

---

**Additional +securities to be quoted in an existing class issued under an +employee incentive scheme**

**FROM (Existing Class)**

**ASX +security code and description**

SPLAK : PERFORMANCE RIGHT

**TO (Existing Class)**

**ASX +security code and description**

SPL : ORDINARY FULLY PAID

**Please state the number of +securities issued under the +employee incentive scheme that are not subject to a restriction on transfer or that are to be quoted notwithstanding there is a restriction on transfer**

121,082

**Please provide details of a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms**

<https://starpharma.com/assets/asxannouncements/201019%20SPL%202020%20Notice%20of%20AGM.pdf>

**Are any of these +securities being issued to +key management personnel (KMP) or an +associate**

☒ No

**Issue date**

6/10/2023

**Will the +securities to be quoted rank equally in all respects from their issue date with the existing issued +securities in that class?**

☒ Yes



Issue details

---

**Number of +securities to be quoted**

121,082

**Are the +securities being issued for a cash consideration?**

☒ No

**Please describe the consideration being provided for the +securities**

Securities being issued are on conversion of employee performance rights at no cost.

**Please provide an estimate (in AUD) of the value of the consideration being provided per +security for the +securities to be quoted**

0.000000

**Any other information the entity wishes to provide about the +securities to be quoted**

Part 4 - Issued capital following quotation

---

Following the quotation of the +securities the subject of this application, the issued capital of the entity will comprise:

(A discrepancy in these figures compared to your own may be due to a matter of timing if there is more than one application for quotation/issuance currently with ASX for processing.)

**4.1 Quoted +securities (total number of each +class of +securities quoted on ASX following the +quotation of the +securities subject of this application)**

ASX +security code and description	Total number of +securities on issue
SPL : ORDINARY FULLY PAID	410,614,159

**4.2 Unquoted +securities (total number of each +class of +securities issued but not quoted on ASX)**

ASX +security code and description	Total number of +securities on issue
SPLAK : PERFORMANCE RIGHT	17,427,803



## Part 5 - Other Listing Rule requirements

---

**5.1 Are the +securities being issued under an exception in Listing Rule 7.2 and therefore the issue does not need any security holder approval under Listing Rule 7.1?**

☒ Yes

**5.1a Select the number of the applicable exception in Listing Rule 7.2**

13